Journal
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Volume 5, Issue 5, Pages 255-266Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285612453972
Keywords
Delta-9-tetrahydrocannabinol; cannabidiol; multiple sclerosis; spasticity; nabiximols
Categories
Funding
- Bayer Health Care
- Biogen Idec
- Merck Serono
- Novartis
- Sanofi Aventis
- TEVA
Ask authors/readers for more resources
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Delta-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available